CathWorks announces EU MDR approval, prominent presence at EuroPCR and full launch of co-promotion

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

$650 Annually

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

CathWorks announces EU MDR approval, prominent presence at EuroPCR and full launch of co-promotion

Posted: 05/13/2024
Physiology 2024 News Articles Imaging & Physiology FFR

Newport Beach, CA & Amsterdam, Netherlands (May 13, 2024) CathWorks announced today that the CathWorks FFRangio® System is now approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR, and fulfills the requirements for CE marking (0344).
1-3 of 2699 results
1 2 3 4 5 Next »

Recurrent Rejection Raises Graft Rejection Risk in Pediatric Heart Transplant: PHTS Analysis

Nov 20, 2024 by
Natalie Morrison, CRTonline.org

Children who experience recurrent mixed or antibody-mediated rejection episodes of heart transplants face a higher risk of losing their graft, according to a new multi-institutional analysis.

Both Social and Genetic Factors Can Boost CHD Risk Prediction Accuracy: New AoU Analysis

Nov 19, 2024 by
Natalie Morrison, CRTonline.org

Both genetic and social factors should play a joint role in boosting the accuracy of risk modeling for coronary heart disease (CHD), said the authors of a new analysis of the ‘All of Us’ (AoU) program, stressing that racial identity is a crucial driver behind bigger social burden.

Halting HF Treatment Poses Risk of Rapid Health Decline, Review Warns

Nov 19, 2024 by
Will Chu, CRTonline.org

A recent review reveals the significant risks heart failure patients face if they discontinue long-term drug treatments, which can include a rapid return to baseline and worsening rebound.

1-3 of 2699 results
1 2 3 4 5 Next »

Most Viewed Pages

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

CathWorks announces EU MDR approval, prominent presence at EuroPCR and full launch of co-promotion

Recurrent Rejection Raises Graft Rejection Risk in Pediatric Heart Transplant: PHTS Analysis

Both Social and Genetic Factors Can Boost CHD Risk Prediction Accuracy: New AoU Analysis

Halting HF Treatment Poses Risk of Rapid Health Decline, Review Warns

Most Viewed Pages

Explore the Site

Stay Connected